Adherex Technologies (ADHXF) 0.7600 $ADHXF
Adherex Announces Share Consolidation, Name Change and Trading Symbol Change
Marketwire - Wed Sep 03, 9:24AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) (the "Company"
announced today that it gave effect to the consolidation of its outstanding share capital on the basis of one new security for every three outstanding securities (the "Consolidation" . In addition, the Company filed a Notice of Alteration with the British Columbia Registrar of Companies changing the name of the Company from Adherex Technologies Inc. to Fennec Pharmaceuticals Inc. to better reflect its current business focus and activities (the "Name Change" . The Company's Common Shares post-Consolidation will trade on the TSX Exchange under a new trading symbol: FRX.
Adherex Provides Corporate Update and Second Quarter Ended June 30, 2014 Financial Results
Marketwire - Mon Aug 11, 7:36AM CDT
Adherex Technologies Inc. (TSX: AXH)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2014. All amounts are in US dollars unless otherwise specified.
Adherex Announces Warrant Exchange Results and New Capital Structure
Marketwire - Fri Aug 08, 7:01AM CDT
Adherex Technologies Inc. (TSX: AXH)(OTCQB: ADHXF), today reported the final results of the Warrant exchange which concluded on July 29, 2014. Approximately, 71% of all outstanding warrants originally issued by the Company on April 30, 2010 and 48% of all outstanding warrants issued on March 29, 2011 participated in the exchange. The new capital structure of the Company post the exchange is as follows:
Adherex Technologies Inc. Announces Warrant Exchange
Marketwire - Mon Jun 30, 7:31AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) (the "Company" today announced it is offering holders of warrants originally issued by the Company on or about April 30, 2010 and March 29, 2011 the opportunity to exchange 180 warrants for one new warrant to purchase one share of common stock at a lower exercise price. Each 18 warrants eligible to participate in the exchange currently entitle the holder thereof to purchase one share of the Company's common stock at an exercise price of CAD$1.44. The new warrants issued in the exchange will entitle the holder thereof to purchase one share of the Company's common stock at an exercise price of US$0.50. Other than described above, the new warrants will have the same terms (including the same expiration date) as the warrants that are exchanged. The offer to exchange eligible warrants for new warrants will expire on July 29, 2014, unless extended to a later date by the Company. Some of the warrants eligible to participate in the exchange are listed on the Toronto Stock Exchange and trade under the symbol AHX.WT. The Company does not intend to list the new warrants on any securities exchange.
Adherex Provides Corporate Update and Fiscal Year Ended December 31, 2013 Financial Results
Marketwire - Mon Mar 31, 7:04AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the year ended December 31, 2013. All amounts are in US dollars unless otherwise specified.
OTC Signal Daily Stock Watch - Adherex Technologies Inc. (OTCQB: ADHXF)
WorldStockWire - Thu Sep 12, 2:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Adherex Announces Corporate Update
Marketwire - Thu Aug 15, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) announced today that David Lieberman has resigned from the Board of Directors. Rosty Raykov, CEO and a director of Adherex, will assume the role of Chairman of the Board of Directors. Robert Andrade has resigned as Chief Financial Officer and a director of the Company. Krysia Lynes, who has solid accounting background and has worked for Adherex since July 2010, will assume the role of Chief Financial Officer on an interim basis.
Adherex Reports Recent Developments and Second Quarter June 30, 2013 Financial Results
Marketwire - Fri Aug 09, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Reports Feedback from the FDA from End of Phase 2 Meeting
Marketwire - Thu May 23, 8:07PM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer (MBC) patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinical study addressing the special ability of eniluracil/5-FU/leucovorin to meet the medical needs of these patients. However, the agency strongly recommended that Adherex consider other larger clinical trial design alternatives for the future development of eniluracil in MBC. In light of the Company's limited resources, Adherex is taking the Agency's recommendations into consideration as it reviews the feasibility of these and other clinical options.
Adherex Reports Recent Developments and First Quarter March 31, 2013 Financial Results
Marketwire - Mon May 13, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results and recent developments for the first quarter ended March 31, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Announces Share Consolidation, Name Change and Trading Symbol Change
Marketwire - Wed Sep 03, 9:24AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) (the "Company"
announced today that it gave effect to the consolidation of its outstanding share capital on the basis of one new security for every three outstanding securities (the "Consolidation" . In addition, the Company filed a Notice of Alteration with the British Columbia Registrar of Companies changing the name of the Company from Adherex Technologies Inc. to Fennec Pharmaceuticals Inc. to better reflect its current business focus and activities (the "Name Change" . The Company's Common Shares post-Consolidation will trade on the TSX Exchange under a new trading symbol: FRX. Adherex Provides Corporate Update and Second Quarter Ended June 30, 2014 Financial Results
Marketwire - Mon Aug 11, 7:36AM CDT
Adherex Technologies Inc. (TSX: AXH)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2014. All amounts are in US dollars unless otherwise specified.
Adherex Announces Warrant Exchange Results and New Capital Structure
Marketwire - Fri Aug 08, 7:01AM CDT
Adherex Technologies Inc. (TSX: AXH)(OTCQB: ADHXF), today reported the final results of the Warrant exchange which concluded on July 29, 2014. Approximately, 71% of all outstanding warrants originally issued by the Company on April 30, 2010 and 48% of all outstanding warrants issued on March 29, 2011 participated in the exchange. The new capital structure of the Company post the exchange is as follows:
Adherex Technologies Inc. Announces Warrant Exchange
Marketwire - Mon Jun 30, 7:31AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) (the "Company"
today announced it is offering holders of warrants originally issued by the Company on or about April 30, 2010 and March 29, 2011 the opportunity to exchange 180 warrants for one new warrant to purchase one share of common stock at a lower exercise price. Each 18 warrants eligible to participate in the exchange currently entitle the holder thereof to purchase one share of the Company's common stock at an exercise price of CAD$1.44. The new warrants issued in the exchange will entitle the holder thereof to purchase one share of the Company's common stock at an exercise price of US$0.50. Other than described above, the new warrants will have the same terms (including the same expiration date) as the warrants that are exchanged. The offer to exchange eligible warrants for new warrants will expire on July 29, 2014, unless extended to a later date by the Company. Some of the warrants eligible to participate in the exchange are listed on the Toronto Stock Exchange and trade under the symbol AHX.WT. The Company does not intend to list the new warrants on any securities exchange. Adherex Provides Corporate Update and Fiscal Year Ended December 31, 2013 Financial Results
Marketwire - Mon Mar 31, 7:04AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the year ended December 31, 2013. All amounts are in US dollars unless otherwise specified.
OTC Signal Daily Stock Watch - Adherex Technologies Inc. (OTCQB: ADHXF)
WorldStockWire - Thu Sep 12, 2:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Adherex Announces Corporate Update
Marketwire - Thu Aug 15, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) announced today that David Lieberman has resigned from the Board of Directors. Rosty Raykov, CEO and a director of Adherex, will assume the role of Chairman of the Board of Directors. Robert Andrade has resigned as Chief Financial Officer and a director of the Company. Krysia Lynes, who has solid accounting background and has worked for Adherex since July 2010, will assume the role of Chief Financial Officer on an interim basis.
Adherex Reports Recent Developments and Second Quarter June 30, 2013 Financial Results
Marketwire - Fri Aug 09, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Reports Feedback from the FDA from End of Phase 2 Meeting
Marketwire - Thu May 23, 8:07PM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer (MBC) patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinical study addressing the special ability of eniluracil/5-FU/leucovorin to meet the medical needs of these patients. However, the agency strongly recommended that Adherex consider other larger clinical trial design alternatives for the future development of eniluracil in MBC. In light of the Company's limited resources, Adherex is taking the Agency's recommendations into consideration as it reviews the feasibility of these and other clinical options.
Adherex Reports Recent Developments and First Quarter March 31, 2013 Financial Results
Marketwire - Mon May 13, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results and recent developments for the first quarter ended March 31, 2013. All amounts are in U.S. dollars unless otherwise specified.
